Topas Therapeutics GmbH based in Hamburg has signed a multi-year agreement with Boehringer Ingelheim to collaborate on antigen-specific tolerance induction focusing on virus-based delivery vectors that create novel therapeutics for patients, a press release said Tuesday (April 24, 2018).
Nanoparticle technology to prevent vector-neutralizing responses
Virus-based therapeutics are emerging as a promising new approach to treat cancer with applications such as oncolytic viruses and delivery vectors for cancer vaccines. However, the body may develop an unwanted immune reaction, prohibiting repeated administration of the viral therapeutic and possibly limiting it’s use. The tolerizing nanoparticle technology by Topas aims to prevent this vector-neutralizing response.
Under the agreement, Topas will be responsible for the design, application and production of the proprietary tolerizing particle. Boehringer Ingelheim will contribute it’s antigen know-how and pharmacology expertise to develop tolerance-generating adjuvant candidates. Boehringer Ingelheim has an option to license several pre-clinical development candidates produced under the collaboration for development and commercialization.
Precise delivery of novel therapeutics
Timm Jessen, CEO of Topas Therapeutics, said: “We are proud to be working with Boehringer Ingelheim to generate novel product candidates using our proprietary technology. This collaboration supports the value and broad applicability of our tolerance induction approach, now comprising the increasingly significant field of novel therapeutics and their precise delivery. The high level of interest we have seen in our technology, including this key collaboration with Boehringer Ingelheim, supports the growing recognition of the importance of tolerance induction in drug development, and we believe will fuel Topas’ future commercial potential.”